Published recently in the journal Frontiers in Nutrition, the report is the first evaluation of the use of ketogenic metabolic therapy (KMT) without chemo or radiation interventions, on a patient ...

They discuss the importance of molecular testing, particularly for IDH1 or IDH2 mutations and outstanding questions for treatment of patients with oligodendrogliomas and astrocytomas. Read the latest ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

NEO100-01, an intranasal perillyl alcohol therapy, targets IDH1-mutant astrocytomas, aiming to bypass the blood-brain barrier. The phase 2a trial is nearing full enrollment, conducted at seven U.S.